© 2005-2012 American Society of Clinical Oncology (ASCO). All rights reserved worldwide.
Cancer.Net Associate Editor: Melanoma and Skin Cancer
University of Pennsylvania Abramson Cancer Center
Lynn M. Schuchter, MD, is the University of Pennsylvania's C. Willard Robinson Professor of Hematology/Oncology, Chief of the Hematology/Oncology Division, and Program Leader for the Abramson Cancer Center's National Cancer Institute approved and funded Melanoma and Cutaneous Malignancies Research Program. Dr. Schuchter is a recognized expert in the field of melanoma and an experienced investigator in the development and conduct of melanoma clinical trials. She has been the principal investigator of numerous phase I, phase II, and phase III melanoma clinical trials. Dr. Schuchter served as Co-PI of the Penn/Wistar Skin Cancer SPORE. In addition, she serves as a scientific advisor to the NCI P01, “Human Melanoma: Etiology, Progression and Therapy” (M.Herlyn, PI), and she is Co-Investigator on a recently awarded P01- “Targeted Therapy of Melanoma”, (Herlyn, M, PI). She is a member of the board of the Melanoma Research Foundation (MRF), a nationwide organization that is the largest advocate group for this disease. She also serves on the Scientific Advisory Committee of the MRF and on the ASCO Board of Directors.
After earning a bachelor's degree from the University of Michigan, Dr. Schuchter earned her medical degree at the Chicago School of Medicine. She completed her fellowship in medical oncology at the Johns Hopkins Oncology Center.
Disclosure: In the past two years, Dr. Schuchter received research funding from Pfizer, GlaxoSmithKline, Merck, Roche, and Genentech.
Last Updated: November 07, 2011